Merrimack Pharmaceuticals Inc (MACK) - Financial and Strategic SWOT Analysis Review

November 2021 | 39 pages | ID: M6DAD833A3FEN
GlobalData

Abstracts

Merrimack Pharmaceuticals Inc (MACK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Merrimack Pharmaceuticals Inc (Merrimack) is a clinical stage biopharmaceutical company that develops and commercializes novel targeted solutions for the treatment of various types of cancers through its understanding of biological markers and cancer pathways. The company's first commercial product was Onivyde (irinotecan liposome injection) a liposomal formulation for treating advanced pancreatic cancer patients. Merrimack is entitled to receive milestone payments related to sale of Onivyde and MM-436 to Ipsen SA. Merrimack is headquartered in Cambridge, Massachusetts, the US.

Merrimack Pharmaceuticals Inc Key Recent Developments

Nov 04,2021: Merrimack Reports Third Quarter 2021 Financial Results
Aug 05,2021: Merrimack Reports Second Quarter 2021 Financial Results
Mar 10,2021: Merrimack reports full year 2020 financial results
Nov 05,2020: Merrimack reports third quarter 2020 financial results
Aug 07,2020: Merrimack reports second quarter 2020 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Merrimack Pharmaceuticals Inc - Key Facts
Merrimack Pharmaceuticals Inc - Key Employees
Merrimack Pharmaceuticals Inc - Key Employee Biographies
Merrimack Pharmaceuticals Inc - Major Products and Services
Merrimack Pharmaceuticals Inc - History
Merrimack Pharmaceuticals Inc - Company Statement
Merrimack Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Merrimack Pharmaceuticals Inc - Business Description
Merrimack Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Merrimack Pharmaceuticals Inc - Strengths
Merrimack Pharmaceuticals Inc - Weaknesses
Merrimack Pharmaceuticals Inc - Opportunities
Merrimack Pharmaceuticals Inc - Threats
Merrimack Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Merrimack Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 04, 2021: Merrimack Reports Third Quarter 2021 Financial Results
Aug 05, 2021: Merrimack Reports Second Quarter 2021 Financial Results
Mar 10, 2021: Merrimack reports full year 2020 financial results
Nov 05, 2020: Merrimack reports third quarter 2020 financial results
Aug 07, 2020: Merrimack reports second quarter 2020 financial results
May 07, 2020: Merrimack reports first quarter 2020 financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Merrimack Pharmaceuticals Inc, Key Facts
Merrimack Pharmaceuticals Inc, Key Employees
Merrimack Pharmaceuticals Inc, Key Employee Biographies
Merrimack Pharmaceuticals Inc, Major Products and Services
Merrimack Pharmaceuticals Inc, History
Merrimack Pharmaceuticals Inc, Subsidiaries
Merrimack Pharmaceuticals Inc, Key Competitors
Merrimack Pharmaceuticals Inc, Ratios based on current share price
Merrimack Pharmaceuticals Inc, Annual Ratios
Merrimack Pharmaceuticals Inc, Annual Ratios (Cont...1)
Merrimack Pharmaceuticals Inc, Interim Ratios
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Merrimack Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Merrimack Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Merrimack Pharmaceuticals Inc, Ratio Charts
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021